Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung

Nivolumab, a fully humanized monoclonal IgG4 antibody blocking programmed cell death-1 (PD-1), has demonstrated improved survival over docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) (1,2). Vitiligo-like depigmentation is a well described immune-related adverse event (irAE) in melanoma patients receiving immunotherapy with PD-1 inhibitors but it’s rare in NSCLC (3). We experienced a rare case of metastatic NSCLC who developed vitiligo-like lesions during nivolumab treatment after excess sunburn. We presented clinical course of this patient with the data of histological and immunohistochemical analysis of the skin lesions.